MIRA INFORM REPORT

 

 

Report Date :           

11.01.2012

 

IDENTIFICATION DETAILS

 

Name :

TOMITA PHARMACEUTICAL CO LTD

 

 

Registered Office :

85-1 Maruyama Akinokami Setocho Naruto City Tokushima-Pref 771-0360

 

 

Country :

Japan

 

 

Financials (as on) :

31.03.2011

 

 

Date of Incorporation :

July 1955

 

 

Legal Form :

Limited Company

 

 

Line of Business :

Manufacturer of inorganic pharmaceutical products

 

 

No. of Employees :

372

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

Yen 346.8 Million

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

---

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – September 30th, 2011

 

Country Name

Previous Rating

                   (30.06.2011)                  

Current Rating

(30.09.2011)

Japan

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

Company name

 

TOMITA PHARMACEUTICAL CO LTD

 

 

REGD NAME

 

Tomita Seiyaku KK

 

 

MAIN OFFICE

 

85-1 Maruyama Akinokami Setocho Naruto City Tokushima-Pref 771-0360, JAPAN

Tel: 088-688-0511      Fax: 088-688-0565

                                               

URL:                             http://www.tomitaph.co.jp

E-Mail address:                        webmaster@tomitaph.co.jp

 

 

ACTIVITIES

 

Mfg of inorganic pharmaceutical products

 

 

BRANCHES

 

Tokyo, Osaka, Nagoya

 

 

OVERSEAS

 

New Jersey (USA)

 

 

FACTORIES

 

At the caption address

 

 

OFFICERS

 

SUMIHIRO TOMITA, PRES         Yutaka Kanamori, dir

Keiji Takamaru, dir                     Hideyuki Aoyama, dir

Mineaki Kabayama, dir               Hitoshi Noguchi, dir                   

 

Yen Amount:     In million Yen, unless otherwise stated

 

 

SUMMARY

 

FINANCES                    FAIR                             A/SALES          Yen 10,078 M

PAYMENTS                  REGULAR                     CAPITAL           Yen 96 M

TREND             STEADY                       WORTH            Yen 5,672 M

STARTED                     1955                             EMPLOYES      372

 

 

COMMENT    

 

MFR OF INORGANIC PHARMACEUTICAL PRODUCTS.

 

FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.

                       

MAX CREDIT LIMIT: YEN 346.8 MILLION, 30 DAYS NORMAL TERMS

 

 

HIGHLIGHTS

           

The subject company was established originally in 1872 when Kyusaburo Tomita started research in pharmaceuticals, on his account.  Incorporated in 1955 the firm has been succeeded by his descendants.  This is a specialized mfr of inorganic pharmaceutical products (See OPERATION).  Clients include major pharmaceutical makers, wholesalers, other, nationwide.

 

 

FINANCIAL INFORMATION

 

The sales volume for Mar/2011 fiscal term amounted to Yen 10,078 million, an almost similar amount in the previous term.  The recurring profit was posted at Yen 582 million and the net profit at Yen 391 million, respectively, compared with Yen 623 million recurring profit and Yen 424 million net profit, respectively, a year ago.

 

For the current term ending Mar 2012 the recurring profit is projected at Yen 600 million and the net profit at Yen 400 million, on a 5% rise in turnover, to Yen 10,600 million.

 

The financial situation is considered FAIR and good for ORDINARY business engagements.  Max credit limit is estimated at Yen 346.8 million, on 30 days normal terms.

 

 

REGISTRATION

 

Date Registered:  Jul 1955

Legal Status:      Limited Company (Kabushiki Kaisha)

Authorized:         768,000 shares

Issued:                192,000 shares

Sum:                   Yen 96 million

Major shareholders (%): Sumihiro Tomita (34.3), Tomita Shoji (19.7), Employees’ S/Holding Assn

(17.6), Toshie Tomita (4.2), Kazunori Tomita (4.2)

No. of shareholders: 25

 

Nothing detrimental is known as to the commercial morality of executives.

 

 

OPERATION

           

Activities: Manufactures dialysis agents (powder) (59%), sodium sulfate (5%), magnesium chloride (6%), antacids (9%), others (21%).

 

Exports (13%)

 

Clients: [Mfrs, wholesalers] Nakao Pharmaceuticals, Takeda Pharmaceutical Co, Konica Minolta Co, Fuso Pharmaceutical Ind, other

            No. of accounts: 500

            Domestic areas of activities: Nationwide

Suppliers: [Mfrs, wholesalers] Nakao Pharmaceutical, Fuso Pharmaceutical Ind, Nippon Salt Mfg, Otsuka Chemical, Ube Materials, other

 

Payment record: Regular

 

Location: Business area in Naruto City, Tokushima-Pref.  Office premises at the caption address are owned and maintained satisfactorily.

 

Bank References:

·         Shoko Chukin Bank (Tokushima)

·         MUFG (Tokushima)

Relations: Satisfactory        

 

FINANCES

(In Million Yen)

 

       Terms Ending:

31/03/2012

31/03/2011

31/03/2010

31/03/2009

Annual Sales

　

10,600

10,078

10,019

9,504

Recur. Profit

　

600

582

623

320

Net Profit

　

400

391

424

319

Total Assets

　

　

11,066

10,582

10,223

Current Assets

　

　

7,168

6,799

　

Current Liabs

　

　

3,403

3,205

　

Net Worth

　

　

5,672

5,319

4,924

Capital, Paid-Up

　

　

96

96

96

Div.P.Share(¥)

　

　

200.00

200.00

150.00

<Analytical Data>

(%)

(%)

(%)

(%)

    S.Growth Rate

5.18

0.59

5.42

4.69

    Current Ratio

 

..

210.64

212.14

..

    N.Worth Ratio

..

51.26

50.26

48.17

    R.Profit/Sales

 

5.66

5.77

6.22

3.37

    N.Profit/Sales

3.77

3.88

4.23

3.36

    Return On Equity

..

6.89

7.97

6.48

 

Notes: Forecast (or estimated) figures for the 31/03/2012 fiscal term.

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.52.23

UK Pound

1

Rs.80.84

Euro

1

Rs.66.79

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.